LHX vs RAPP · P/E 34, rev $5.88B vs rev $20.0M
L3Harris Technologies Inc (LHX) versus Rapport Therapeutics, Inc. Common Stock (RAPP) — a side-by-side from cached financials, not a winner call.
L3Harris Technologies Inc (LHX) is a aerospace & defense company listed on US.
Rapport Therapeutics, Inc. Common Stock (RAPP) is a biotechnology company listed on US.
Latest reported LHX revenue for 2026-07-03 was $5.88B. Net income was $600.0M. Revenue was up 2.4% from 2026-04-03 to 2026-07-03. LHX currently screens at market cap $58.72B and trailing P/E 34.3.
Latest reported RAPP revenue for 2026-06-30 was $20.0M. Net income was -$76.5M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. RAPP currently screens at market cap $532.9M.
LHX currently screens at market cap $58.72B and trailing P/E 34.3. RAPP currently screens at market cap $532.9M.
Not investment advice. Open the LHX and RAPP stock pages for the full models.
Not investment advice.